secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001628280-25-022397
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q1 total revenue $65.0M (-53% Y/Y); US product revenue up 41% to $34.9M
--------------------------------------------------------------------------------

- Net loss $40.5M ($0.21 EPS loss) vs net income $61.0M ($0.36 EPS) in Q1 2024 due to prior-year milestone.
- Collaboration revenue $30.1M (-73% Y/Y) on $100M milestone in Q1 2024; ex-milestone +97%.
- Commercial: surpassed 1M US prescriptions; reimbursement team expanded from 5 to 15 specialists.
- Pipeline: unveiled PSC candidate ESP-1336 (>$1B market); triple-combination products on track for 2027.
- 2025 op-ex guidance $215-235M (incl. ~$15M stock comp); cash $114.6M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025022397/0001628280-25-022397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025022397/espr-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-022397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer